Skip to main content
. 2018 Jun 12;4:JGO.18.00018. doi: 10.1200/JGO.18.00018

Fig 1.

Fig 1

Comparison of median overall survival (OS) between patients with colorectal cancer and type II diabetes mellitus treated with metformin (group A, green line) and those treated with other antidiabetic medications (group B, blue line). The median OS was 89 months (95% CI, 66 to 112 months) for group A and 36 months for group B (95% CI, 24 to 48 months; P < .001). The 5-year OS rate was 58% for group A and 32% for group B.